{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-000578","form_type":"8-K","ticker":"LFWD","cik":"0001607962","company_name":"Lifeward Ltd.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.631307+00:00","generated_at":"2026-05-16T01:44:51.376971+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lifeward enters $525K secured note with Oramed at 24% interest, expandable by $975K","bullets":["Initial principal $525,000; mutual consent can increase by up to $975,000 for total up to $1.5M.","Interest at 24% per annum; matures earlier of August 12, 2026 or failure to obtain shareholder approval.","Note secured by lien on company's cash; proceeds applied ratably with existing $3M secured note.","Customary covenants limit additional debt, liens, asset sales, and affiliate transactions.","Events of default include non-payment, covenant breach, insolvency, or material adverse effect."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-000578","json":"https://secwatch.observer/filing/0001178913-26-000578.json","markdown":"https://secwatch.observer/filing/0001178913-26-000578.md","text":"https://secwatch.observer/filing/0001178913-26-000578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326000578/0001178913-26-000578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326000578/zk2634413.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:44:51.376971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"800b2ab62a806e4683233ad6739123866620cd70","claim":"Lifeward Ltd. incurred loan of initial principal amount of $525,000 with Oramed Pharmaceuticals, Inc. at 24% per annum maturing the earlier of (i) August 12, 2026 and (ii) the failure of the Company to obtain shareholder approval.","evidence_excerpt":"On February 12, 2026, the Company entered into a Secured Promissory Note (the “Subsequent Secured Promissory Note”) with Oramed Pharmaceuticals, Inc. (“Oramed”) pursuant to which the Company issued to Oramed a secured promissory note in the initial principal amount of $525,000","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326000578/0001178913-26-000578-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"initial principal amount of $525,000"},{"label":"Counterparty","value":"Oramed Pharmaceuticals, Inc."},{"label":"Rate","value":"24% per annum"},{"label":"Maturity","value":"the earlier of (i) August 12, 2026 and (ii) the failure of the Company to obtain shareholder approval"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"9902bc5828de0b749681e795aae24b677c495942","claim":"Lifeward Ltd. entered into Subsequent Secured Promissory Note with Oramed Pharmaceuticals, Inc. valued at initial principal amount of $525,000, which amount may be increased by up to an additional $975,000 (effective 2026-02-12).","evidence_excerpt":"On February 12, 2026, the Company entered into a Secured Promissory Note (the “Subsequent Secured Promissory Note”) with Oramed Pharmaceuticals, Inc. (“Oramed”) pursuant to which the Company issued to Oramed a secured promissory note in the initial principal amount of $525,000, which amount may be increased by up to an additional $975,000 upon the mutual consent of the parties.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326000578/0001178913-26-000578-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Oramed Pharmaceuticals, Inc."},{"label":"Value","value":"initial principal amount of $525,000, which amount may be increased by up to an additional $975,000"},{"label":"Effective","value":"2026-02-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}